I, K., P, S., MI, H., A, C., A, A. K., A, S., . . . ABM, K. (2026). Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. https://doi.org/10.1016/j.eprac.2026.06.004
Chicago Style (17th ed.) CitationI, Khalil, et al. "Efficacy of Initiation of Semaglutide Versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study." Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026. https://doi.org/10.1016/j.eprac.2026.06.004.
MLA (9th ed.) CitationI, Khalil, et al. "Efficacy of Initiation of Semaglutide Versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study." Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026, https://doi.org/10.1016/j.eprac.2026.06.004.
